Testing the shingles vaccine response after bone marrow transplant
Treatments studied
Part of Infections clinical trials.
This Phase 2 study looks at how well the shingles vaccine works in people who had an allogeneic (donor) stem cell transplant. It aims to measure the body’s immune response to the vaccine and check that it’s safe in this recovery period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are 12 to 36 months after your donor stem cell transplant
- Your transplant donor source was a matched relative, matched unrelated donor, or cord blood
- You have (or previously had) a blood cancer or blood-related illness, and you are not currently experiencing a relapse
- You are medically well enough for vaccination (not acutely ill) and can do intramuscular injections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the shingles vaccine in young adults who have had a solid organ transplant (like a kidney or liver) more than a year ago. The goal is to see if the vaccine works well and is safe for people on stable anti-rejection medicines.
This Phase 2 study tests whether an additional Shingrix (RZV) vaccine dose helps prevent shingles in people who previously had an allogeneic bone marrow or stem cell transplant. It focuses on people who are at least a year out from their first two Shingrix doses.
This trial tests whether the shingles vaccine (RZV) is safe and works well for organ transplant recipients and their household members. It also includes people on dialysis or certain immunosuppressants.
This study tests whether an extra dose of the Shingrix shingles vaccine can boost your protection against shingles after an organ transplant. It may help you stay healthier by strengthening your immune system's defenses.
This Phase 3 study tests whether the shingles vaccine Shingrix is safe and effective for adults with chronic kidney failure who are on the transplant waiting list. It aims to protect you from shingles while you may be dealing with transplant-related immune changes.
This Phase 1/2 study tests how safe and how well a shingles (varicella zoster) vaccine works in adults living with HIV whose immune status is measured by CD4 count, plus a healthy comparison group. It may help researchers understand whether the vaccine can safely boost protection in people with HIV.
Hear when a new Shingles trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.